In conclusion, by combining molecular profiling with chemical imaging, we have demonstrated that mammary tissue fibroblasts can alter therapeutic response to anticancer agents and play a crucial role in controlling whether ER+ breast cancer cells are able to respond well to hormone or become resistant to endocrine therapies. The gene discussed is ESR1; the disease is breast carcinoma.